类风湿关节炎生物治疗新突破-托珠单抗

Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to the destruction of synovial joints. Chronic inflammation runs throughout the entire course of RA, and cardiovascular disease (CVD) is the most serious complication of RA. Compared with the general population, patients with RA have a 1.5-fold increased risk of CVD episodes, a 2-fold increased risk of heart failure, and a higher risk of peripheral vascular disease. , a monoclonal antibody against IL-6 receptor, blocks the signaling process of IL-6 and has certain therapeutic significance in RA.

About tocilizumab

托珠单抗(tocilizumab)是一种针对人类白细胞介素-6受体（IL-6R）的经过人源化的单克隆抗体，是现在 bDMARDS 中应用较为广泛且效果较明确的一种,最早于2005年于日本市场上市，并于2013年获得中国药品监督管理局批准。 Tocilizumab can specifically bind to IL-6R in the human body and plays a role in the treatment of RA by blocking IL-6, an important target. The results of multiple clinical studies have shown that TCZ is safe and effective in some patients who are insensitive to anti-TNF-α therapy.

Cacciapaglia et al.'s study showed that TG, TC, LDIL-C, and HDL-C levels increased after 6 months of using tocilizumab and returned to close to baseline levels at 52 weeks. In five phase 3 double-blind trials using tocilizumab, the rate of myocardial infarction was reduced compared with the control group.而对托珠单抗长期安全性的评估表明,使用托珠单抗后的CVD事件的发生率下降而对托珠单抗长期安全性的评估表明，使用托珠单抗后的CVD事件的发生率下降。

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.